Picard Medical Business Summary

Picard Medical, Inc. (PMI) operates as a commercial-stage medical technology company primarily through its wholly owned subsidiary, SynCardia Systems, LLC, the manufacturer of the world’s only FDA-approved and commercially available Total Artificial Heart (TAH). The company generates revenue through a direct sales and licensing model, providing the SynCardia TAH system, external pneumatic drivers (for hospital and home use), and specialized drivelines to transplant centers globally. Its business is segmented into clinical support for end-stage biventricular heart failure, focusing on the Bridge to Transplantation (BTT) market, with active expansion into Bridge to Candidacy (BTC) and long-term destination therapy. PMI competes directly with Carmat (Aeson TAH), BiVACOR, and Orchestra BioMed, maintaining a unique market position as the sole provider of a clinically validated, pulsatile-flow mechanical replacement for both ventricles and all four heart valves. Leadership is spearheaded by CEO Patrick NJ Schnegelsberg, a veteran medtech executive previously of Syntach AB, and COO Matt Schuster, who oversees the integration of the next-generation "Emperor" fully implantable heart platform. The executive team includes CFO Bernard Skaggs and CTO Frank Tinker, who lead the company’s R&D and financial strategy following its 2025 transition to the NYSE American. The board of directors features high-pedigree industry leaders such as George Ye, a former senior executive at Edwards Lifesciences and Abbott Laboratories, and Sam Van, a former Director of International Listings at the New York Stock Exchange. The company is backed by significant institutional investors, including Hunniwell Picard I, LLC, which maintains a majority controlling interest, and Sindex SSI Financing, LLC.